Sign in Subscribe
United States. Securities and Exchange Commission

Actavis and Allergan Shareholder Meetings Set for March 10, 2015

Strategic Insights

— 2 min read

Actavis plc, a specialty pharmaceutical company, and Allergan, Inc., a multi-specialty healthcare company, announced the scheduling of their respective special meetings of shareholders in connection with the pending acquisition of Allergan by Actavis. The meetings are set to take place on March 10, 2015, at 8:30 a.m. local time at 1 Grand Canal Square, Docklands, Dublin 2, Ireland for Actavis shareholders, and at 10:00 a.m. local time at 2525 Dupont Drive, Irvine, California for Allergan stockholders.

Key Takeaways:

  • The U.S. Securities and Exchange Commission has declared effective Actavis' registration statement on Form S-4 relating to the pending acquisition of Allergan.
  • Actavis and Allergan have scheduled their respective special meetings of shareholders in connection with the pending acquisition for March 10, 2015.
  • The Actavis shareholder meeting will be held at 1 Grand Canal Square, Docklands, Dublin 2, Ireland, while the Allergan stockholder meeting will be held at 2525 Dupont Drive, Irvine, California.
  • Actavis shareholders and Allergan stockholders of record as of January 22, 2015, are entitled to vote at their respective special meetings.
  • Actavis and Allergan expect to begin mailing a joint proxy statement/prospectus to their respective shareholders and stockholders in the coming days, which will contain information for shareholders and stockholders of both companies, as well as instructions for voting.
  • The companies have commercial operations in more than 60 countries and operate more than 30 manufacturing and distribution facilities around the world.
  • Actavis has a broad portfolio of branded and generic pharmaceuticals, while Allergan markets a range of products for optometry, eye care, and women's health, among other areas.
  • The acquisition is subject to regulatory approvals and the receipt of required shareholder approvals.

Statistics:

  • The joint proxy statement/prospectus will contain information for shareholders and stockholders of both companies.
  • The acquisition is expected to be completed in 2015, subject to regulatory approvals and shareholder approvals.
  • Actavis and Allergan have commercial operations in more than 60 countries.
  • Actavis operates more than 30 manufacturing and distribution facilities around the world.
  • The transaction values Allergan at approximately $183 billion, making it one of the largest pharmaceutical acquisitions in history.

Sources:

  • Actavis plc (NYSE: ACT) Press Release: Actavis and Allergan Announce Special Meetings of Shareholders for March 10, 2015 (January 26, 2015)
  • Allergan, Inc. (NYSE: AGN) Press Release: Allergan Announces Special Meeting of Stockholders for March 10, 2015 (January 26, 2015)
  • Registration Statement on Form S-4 filed by Actavis with the U.S. Securities and Exchange Commission (January 26, 2015)

Read more